1. Home
  2. PGZ vs CGTX Comparison

PGZ vs CGTX Comparison

Compare PGZ & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Principal Real Estate Income Fund of Beneficial Interest

PGZ

Principal Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$8.74

Market Cap

66.6M

Sector

Finance

ML Signal

HOLD

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$0.72

Market Cap

79.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGZ
CGTX
Founded
2012
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.6M
79.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PGZ
CGTX
Price
$8.74
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
20.5K
★ 473.0K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 12.26%
N/A
EPS Growth
N/A
★ 62.79
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.70
$0.55
52 Week High
$10.58
$1.83

Technical Indicators

Market Signals
Indicator
PGZ
CGTX
Relative Strength Index (RSI) 32.46 28.18
Support Level N/A $0.55
Resistance Level $10.50 $1.18
Average True Range (ATR) 0.11 0.06
MACD 0.02 -0.01
Stochastic Oscillator 3.85 19.54

Price Performance

Historical Comparison
PGZ
CGTX

About PGZ Principal Real Estate Income Fund of Beneficial Interest

Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: